Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Rigel Pharmaceuticals

This ‘Darling’ Pharma Stock Is Hitting New Highs

Rigel Pharmaceuticals (RIGL) is showing exceptional momentum, setting new 52-week highs on Aug. 22. Shares are up nearly 243% over the past year. The stock is trading above key moving averages and is supported by several “Strong Buy” analyst ratings. Fundamentals show impressive projected earnings growth this year, but both...

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Stocks Under $1 Insiders Are Buying

The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall…

Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022

Expert Ratings for Rigel Pharmaceuticals

Rigel Pharmaceuticals (NASDAQ:RIGL) has observed the following analyst ratings within the last quarter:

Why Rigel Pharmaceuticals Shares Are Falling Today

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

Recap: Rigel Pharmaceuticals Q1 Earnings

Recap: Rigel Pharmaceuticals Q1 Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Preview: Rigel Pharmaceuticals's Earnings

Preview: Rigel Pharmaceuticals's Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $-0.14.

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022

Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and a 52-week-low of $7.66. E2open Parent Holdings closed at $9.37 at the end of the last trading period.

Looking Into Rigel Pharmaceuticals's Return On Capital Employed

Looking Into Rigel Pharmaceuticals's Return On Capital Employed

Rigel Pharmaceuticals (NASDAQ:RIGL) brought in sales totaling $20.41 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.06%, resulting in a loss of $22.64 million.

Recap: Rigel Pharmaceuticals Q4 Earnings

Recap: Rigel Pharmaceuticals Q4 Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Rigel Pharmaceuticals's Earnings Outlook

Rigel Pharmaceuticals's Earnings Outlook

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $-0.13.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Jim Van Meerten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

FreeportMcMoRan

Booz Allen Hamilton

Keefe Bruyette & Woods

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play